Xlife Sciences AG announces exit of 12 project companies to Grupo Landsteiner
Mexican Grupo Landsteiner has signed a binding framework to acquire 12 of Xlife Sciences’ advanced biotech, medtech and digital health projects for a total of USD 450 million, payable in shares of Grupo Landsteiner. The transaction represents a strategic exit for Zurich-based Xlife Sciences, while both organizations enter a long-term strategic collaboration.
Under the agreement, Landsteiner will integrate Xlife Sciences’ platform technologies, biotech programs, medtech devices and AI-enabled solutions into its operations Together, Landsteiner and Xlife will align innovation, production and commercialization capabilities to create a unified engine for sustainable value creation.
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector. The goal is to bridge research and development to healthcare markets. According to the Xlife’s investor presentation its portfolio includes 21 portfolio companies in 4 investment pillars with 33 projects.
Xlife Sciences contributes 12 assets spanning:
- Platform technologies (solubility enhancement, 3D screen printing)
- Biotech (oncology, next-generation gene therapy, TNF-alpha antibody, obesity immunotherapy)
- Medtech (NeuroMex early neurodegeneration screening device)
- AI/digital health (MDR-certified prostate cancer diagnostics)
Structured as an asset purchase, the transaction enables joint execution while allowing Xlife Sciences to continue advancing its innovation model. The newly formed entity, combining Grupo Landsteiner and the acquired Xlife Sciences assets, will serve as a dynamic platform for accelerated development, industrial scale-up and global market expansion. The entity intends to pursue a NASDAQ listing in 2026, leveraging the complementary scientific, operational and financial strengths of both organizations.
Oliver R. Baumann, CEO of Xlife Sciences AG, said: «This collaboration is a decisive step in building a global life sciences platform that combines our scientific innovation with Landsteiner’s operational scale. It positions our assets for near-term commercialization and long-term growth, creating substantial value for our shareholders.»
Miguel Granados, Chairman and CEO of Grupo Landsteiner, added: «Partnering with Xlife Sciences integrates a powerful innovation engine into our commercial infrastructure. Together, we will accelerate scientific progress, expand global market access, and create a sustainable value pathway for investors, partners, and patients.»
Landsteiner Scientific is a leading Mexican pharmaceutical laboratory specializing in the development, manufacture, and commercialization of generic medicines and health supplies. With over 25 years of experience, the company offers a strong portfolio of generic and biotechnological drugs. Landsteiner operates two GMP-certified facilities with over 115 million units annual capacity, 300+ product registrations and deep government and private-sector networks across Latin America. Supported by a workforce of nearly 1.000 employees, Landsteiner is creating revenues of about USD 150 million.
(Press release / SK)